{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:21:37Z","timestamp":1793114497233,"version":"4.5.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,9,3]],"date-time":"2013-09-03T00:00:00Z","timestamp":1378166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>Previously, a pilot genome\u2010wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5\u2010fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC). Here, we conducted a prospective confirmatory study to examine the predictive value of rs9679162 (located on <jats:italic>GALNT14<\/jats:italic> gene) for the therapeutic responses using a split\u2010dose FMP protocol. One hundred and seven advanced HCC patients receiving split\u2010dose FMP therapy were enrolled. All patients were in Barcelona Clinical Liver Cancer Stage C with either main portal vein thrombosis and\/or distant metastasis. Of them, 105 (98.1%) were Child\u2010Pugh classification B. <jats:italic>GALNT14<\/jats:italic> genotype was determined before therapy. Of the patients included, 28 were rs9679162 \u201cTT\u201d and 79 were \u201cnon\u2010TT\u201d (\u201cGG\u201d + \u201cGT\u201d) genotype. The median overall survival, time\u2010to\u2010progression, response rate and disease control rate were (\u201cTT\u201d <jats:italic>versus<\/jats:italic> \u201cnon\u2010TT\u201d) 6.8 <jats:italic>versus<\/jats:italic> 3.9 months (<jats:italic>p<\/jats:italic> &lt; 0.001), 3.9 <jats:italic>versus<\/jats:italic> 2.1 months (<jats:italic>p<\/jats:italic> &lt; 0.001), 28.6% <jats:italic>versus<\/jats:italic> 10.1% (<jats:italic>p<\/jats:italic> = 0.029) and 35.7% <jats:italic>versus<\/jats:italic> 15.2% (<jats:italic>p<\/jats:italic> = 0.030), respectively. Multivariate analysis indicated that rs9679162 genotype was an independent predictor for overall survival (<jats:italic>p<\/jats:italic> = 0.002). Categorical analysis showed that 17 patients with \u201cTT\u201d genotype, tumor size &lt; 10 cm and neutrophils &lt; 74% had a median overall survival of 25.5 months and a therapeutic response rate of 47.1%. In conclusion, this prospective study confirmed that <jats:italic>GALN14<\/jats:italic> genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced HCC patients treated by FMP chemotherapy. Combining <jats:italic>GALNT14<\/jats:italic> genotype and clinical parameters, a subgroup of patients with excellent outcome was identified.<\/jats:p>","DOI":"10.1002\/ijc.28439","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T14:54:39Z","timestamp":1376924079000},"page":"1214-1224","source":"Crossref","is-referenced-by-count":28,"title":["A single nucleotide polymorphism on the <i>GALNT14<\/i> gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma"],"prefix":"10.1002","volume":"134","author":[{"given":"Chau\u2010Ting","family":"Yeh","sequence":"first","affiliation":[{"name":"Liver Research Unit Department of Hepato\u2010Gastroenterology Chang Gung Memorial Hospital Taipei Taiwan"},{"name":"Molecular Medicine Research Center Chang Gung University Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kung\u2010Hao","family":"Liang","sequence":"additional","affiliation":[{"name":"Liver Research Unit Department of Hepato\u2010Gastroenterology Chang Gung Memorial Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen\u2010Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Liver Research Unit Department of Hepato\u2010Gastroenterology Chang Gung Memorial Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming\u2010Ling","family":"Chang","sequence":"additional","affiliation":[{"name":"Liver Research Unit Department of Hepato\u2010Gastroenterology Chang Gung Memorial Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng\u2010Lung","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Chang Gung Memorial Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien\u2010Fu","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology Chang Gung Memorial Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,3]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"153","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"15","author":"Ferlay J","year":"2001","journal-title":"Int J Cancer"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06812.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200203000-00009"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00425-8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-7-790"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20841"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-003-1303-8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.43"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-117"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4298"},{"key":"e_1_2_6_20_1","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non\u2010small cell lung cancer","volume":"8","author":"Lord RV","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0247"},{"key":"e_1_2_6_22_1","first-page":"1091","article-title":"ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum\u2010based chemotherapy","volume":"32","author":"Kamikozuru H","year":"2008","journal-title":"Int J Oncol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2216"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0200-03"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0295"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0243"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500072"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02908-X"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1627"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.05.006"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0598"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-123"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28439","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.28439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.28439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.28439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T04:13:34Z","timestamp":1693973614000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.28439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,3]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/ijc.28439"],"URL":"https:\/\/doi.org\/10.1002\/ijc.28439","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,3]]}}}